Clinical Trials

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

USA
Texas
Dallas

This is a Phase II clinical trial aimed at treating patients with T-cell lymphomas (T-cell blood cancers). The drug consists of a toxin, called diphtheria toxin, which is attached to an antibody that can specifically target cancerous T-cells. Our primary objectives are, therefore, to determine the patient subgroup with respect to disease burden who best responds to this experimental drug in treating CD3 positive T cell malignancies. We will be determining how the patient and their disease respond to this research agent.

For more information: http://clinicaltrials.gov/ct2/show/study/NCT00611208?view=record

Travel & Lodging Defrayment
As a result of study participation, travel will be requested to a participating medical center. Angimmune (the study sponsor) will partially pay to defray travel & lodging costs for a family member to accompany a patient to this trial. Please contact the appropriate Clinical Research Coordinator at the trial site listed below for more information.

University of Texas Southwestern Medical Center - Recruiting
Dallas, Texas, United States, 75390-8562
Contact: Adrian Avila, SC    214-648-5107    adrian.avila@utsouthwestern.edu   
Principal Investigator: Arthur E Frankel, MD 

Link: http://www.utswmedicine.org/conditions-specialties/cancer/clinical-trials/fact-detail.html?primarypurpose=10&studyId=STU%20032013-027